C4XD, Horizon to develop synthetic lethality targets in oncology
C4X Discovery (C4XD) and UK-based gene editing company Horizon Discovery Group have forged an exclusive target discovery partnership in oncology.
C4X Discovery (C4XD) and UK-based gene editing company Horizon Discovery Group have forged an exclusive target discovery partnership in oncology.
Incyte and Innovent Biologics have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte.
Bausch Health Companies has signed an agreement to acquire certain assets of Synergy Pharmaceuticals in a transaction valued at around $200m plus certain assumed liabilities.
Eli Lilly and Company (Lilly) and AC Immune have signed a license and collaboration agreement, potentially worth around CHF1.89bn ($1.9bn), for research and development of tau aggregation inhibitor small molecules for the treatment of neurodegenerative diseases like Alzheimer’s disease (AD).
AMAG Pharmaceuticals has signed an agreement to acquire US-based private biopharmaceutical firm Perosphere Pharmaceuticals.
X-Chem and Almirall have partnered to discover lead compounds for innovative and challenging targets with dermatology applications.
Researchers at the Weizmann Institute of Science in Israel have revealed a previously unknown mechanism underlying anxiety.
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.
Versant Ventures, through a $20m Series A financing, has launched Black Diamond Therapeutics, a biotechnology company focused on developing a new type of precision medicine for cancer.
e-therapeutics has entered into a research collaboration with Danish drug manufacturer Novo Nordisk to discover biological mechanisms and therapies to treat type-2 diabetes.